Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tensopyn is a combination analgesic tablet indicated for the short-term relief of mild to moderate pain associated with tension, such as headaches, muscle pain, and joint pain. It is a small molecule formulation containing four active pharmaceutical ingredients: paracetamol (acetaminophen), codeine phosphate, caffeine, and doxylamine succinate. Paracetamol acts as an analgesic and antipyretic; codeine phosphate is an opioid analgesic that is metabolized to morphine in the liver to provide pain relief; caffeine serves as an adjuvant to enhance the analgesic effect of paracetamol; and doxylamine succinate is a sedating antihistamine that helps alleviate tension. Marketed by Cipla Medpro in South Africa, Tensopyn is a prescription-only medication (Schedule 2) and is recommended for use for no more than five consecutive days due to the risk of codeine dependence and addiction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tensopyn.